丹参酮ⅡA抗ApoE<sup>-/-</sup>小鼠冠心病伴抑郁的作用及机制研究

孔俊虹; 陈弦; 沙晨曦; 龚楚桥; 宋晓龙

doi:10.14148/j.issn.1672-0482.2022.0308

丹参酮ⅡA抗ApoE^-/-小鼠冠心病伴抑郁的作用及机制研究

doi: 10.14148/j.issn.1672-0482.2022.0308

1.
南京中医药大学附属常州市中医医院, 江苏常州 213003
2.
盐城市中医院心内科, 江苏盐城 224001

基金项目:

江苏省中医药局重点项目 ZD201709

常州市卫健委青年人才科技项目 QN201937

详细信息

通讯作者:
孔俊虹, 女, 副主任中医师, 主要从事心血管疾病中医药防治研究, E-mail: dr_kongjh@163.com

中图分类号: R285.5
计量
- 文章访问数: 170
- HTML全文浏览量: 65
- PDF下载量: 25
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-21
- 网络出版日期: 2022-04-13
- 发布日期: 2022-04-10

Study on the Mechanism of Tanshinone ⅡA against Coronary Heart Disease with Comorbid Depression in ApoE^-/- Mice

1.
Changzhou Hospital of TCM Affiliated to Nanjing University of Chinese Medicine, Changzhou 213003, China
2.
Department of Cardiology, Yancheng Hospital of Traditional Chinese Medicine, Yancheng 224001, China

摘要

摘要: 目的研究丹参酮ⅡA对ApoE^-/-小鼠冠心病伴抑郁的影响及作用机制。方法采用高脂饲料喂养ApoE^-/-小鼠, 并进行慢性不可预知温和应急(CUMS)构建冠心病伴抑郁小鼠模型。将小鼠随机分为正常组、模型组、丹参酮ⅡA低剂量组(30 mg · kg^-1)和丹参酮ⅡA高剂量组(60 mg · kg^-1)。采用HE和油红O染色检测ApoE^-/-小鼠心脏主动脉窦的病理变化; 强迫游泳实验(FST)、悬尾实验(TST)和糖水偏好实验(SPT)观察ApoE^-/-小鼠抑郁样行为; ELISA法检测小鼠血脂及炎症因子水平; Western blot检测心脏主动脉窦组织和海马组织的炎症相关蛋白表达水平。结果与正常组相比, 模型组ApoE^-/-小鼠心脏主动脉内膜脂质积累显著增加, 血脂及促炎因子显著升高(P < 0.01), FST和TST不动时间显著增加(P < 0.01), SPT蔗糖偏好率显著降低(P < 0.01)，心脏主动脉窦组织和海马组织中p-GSK3β(Ser9)/GSK3β、p-CREB(Ser133)/CREB和p-NF-κB/NF-κB的比值显著增加(P < 0.01)。与模型组相比, 丹参酮ⅡA高、低剂量组ApoE^-/-小鼠心脏主动脉内膜脂质积累显著减少, 血脂及促炎因子水平显著降低(P < 0.01), FST和TST不动时间显著减少(P < 0.01), SPT蔗糖偏好率显著增加(P < 0.01)。p-GSK3β(Ser9)/GSK3β和p-CREB(Ser133)/CREB的比值进一步呈剂量依赖性增加(P < 0.05, P < 0.01)，p-NF-κB/NF-κB比值呈剂量依赖性降低(P < 0.01)。结论丹参酮ⅡA具有显著的抗ApoE^-/-小鼠冠心病伴抑郁作用, 其机制可能是通过调节GSK3β的表达, 继而影响NF-κB与CREB的活化来实现的。
- 丹参酮ⅡA /
- 冠心病 /
- 抑郁 /
- 炎症 /
- GSK3β /
- NF-κB /
- CREB
Abstract: OBJECTIVE To investigate the effect and mechanism of tanshinone ⅡA against coronary heart disease with comorbid depression in ApoE^-/- mice. METHODS The model of coronary heart disease with comorbid depression was established by feeding high fat diet and carrying out chronic unpredictable mild stress (CUMS). Mice were randomly divided into normal group, model group, tanshinone ⅡA low dose group (30 mg · kg^-1) and tanshinone ⅡA high dose group (60 mg · kg^-1). Hematoxylin-eosin (HE) and oil red O staining were used to detect the pathological changes of cardiac aortic sinus in ApoE^-/- mice. Forced swimming test (FST), tail suspension test (TST) and sucrose preference test (SPT) were used to observe the depression-like behaviors of ApoE^-/- mice. The levels of blood lipid and inflammatory factors were detected by ELISA assay. The expressions of inflammation related proteins in cardiac aortic sinus and hippocampus were detected by Western blot. RESULTS Compared with the normal group, the lipid accumulation in the cardiac aortic intima in the model group increased significantly, the levels of blood lipid and pro-inflammatory factors increased significantly (P < 0.01), the immobility time of FST and TST significantly increased (P < 0.01), while the sucrose preference rate of SPT significantly decreased (P < 0.01), the ratios of p-GSK3β (Ser9)/GSK3β, p-NF-κB/NF-κB and p-CREB (Ser133)/CREB in cardiac aortic sinus and hippocampus increased significantly (P < 0.01). Compared with the model group, the treatment with tanshinone ⅡA significantly reduced the accumulation of lipid in cardiac aortic intima, the levels of blood lipid and pro-inflammatory factors and the immobility time of FST and TST decreased significantly (P < 0.01), the sucrose preference rate of SPT significantly increased (P < 0.01), the ratio of p-NF-κB/NF-κB decreased significantly (P < 0.01), and the ratios of p-GSK3β(Ser9)/GSK3β and p-CREB(Ser133)/CREB increased significantly (P < 0.05, P < 0.01). CONCLUSION Tanshinone ⅡA has a significant effect against coronary heart disease with comorbid depression in ApoE^-/- mice, and its mechanism may be related to the regulation of GSK3β, and further activation of NF-κB and CREB.
- tanshinone ⅡA /
- coronary heart disease /
- depression /
- inflammation /
- GSK3β /
- NF-κB /
- CREB

HTML全文

图 1 丹参酮ⅡA对ApoE^-/-小鼠心电图的影响

Figure 1. Effect of tanshinone ⅡA on the electrocardiogram of ApoE^-/- mice

下载: 全尺寸图片幻灯片

图 2 丹参酮ⅡA对ApoE^-/-小鼠心脏主动脉窦组织结构的影响(HE, ×200)

Figure 2. Effect of tanshinone ⅡA on the tissue structure of cardiac aortic sinus in ApoE^-/- mice (HE, ×200)

下载: 全尺寸图片幻灯片

图 3 丹参酮ⅡA对ApoE^-/-小鼠心脏主动脉窦脂质堆积的影响(油红O, ×200)

Figure 3. Effect of tanshinone ⅡA on the lipid accumulation of cardiac aortic sinus in ApoE^-/- mice (Oil red O, ×200)

下载: 全尺寸图片幻灯片

图 4 丹参酮ⅡA对ApoE^-/-小鼠心脏主动脉窦组织和海马组织炎症相关蛋白表达的影响

注: A.正常组; B.模型组; C.丹参酮ⅡA低剂量组; D.丹参酮ⅡA高剂量组; 与正常组相比, ^##P < 0.01;与模型组相比, ^*P < 0.05，^{* *}P < 0.01。

Figure 4. Effect of tanshinone ⅡA on the expressions of inflammation related proteins in cardiac aortic sinus and hippocampus in ApoE^-/- mice

下载: 全尺寸图片幻灯片

表 1 丹参酮ⅡA对ApoE^-/-小鼠抑郁样行为的影响(x±s, n=9)

Table 1. Effect of tanshinoneⅡA on the depression-like behaviors of ApoE^-/- mice (x±s, n=9)

组别	剂量/(mg·kg^-1)	SPT蔗糖偏好率/%	FST不动时间/s	TST不动时间/s
正常组	-	82.06±5.59	73.92±5.69	79.60±6.99
模型组	-	49.65±5.63^##	124.24±8.97^##	132.10±8.14^##
低剂量组	30	67.34±5.71^**	108.00±10.13^**	109.32±11.21^**
高剂量组	60	75.18±6.64^**△	96.31±7.69^**△	91.53±11.86^**△△
注: 与正常组相比, ^##P < 0.01;与模型组相比, ^{* *}P < 0.01;与低剂量组相比, ^△P < 0.05, ^△△P < 0.01。

下载: 导出CSV

表 2 丹参酮ⅡA对ApoE^-/-小鼠血脂含量的影响(x±s, mmol · L^-1，n=9)

Table 2. Effect of tanshinone ⅡA on the contents of serum lipids in ApoE^-/- mice (x±s, mmol · L^-1, n=9)

组别	剂量/(mg·kg^-1)	TC	TG	HDL-C	LDL-C
正常组	-	48.51±6.16	37.99±4.06	18.14±2.40	30.09±2.92
模型组	-	114.48±6.43^##	88.67±6.71^##	7.40±0.67^##	78.01±5.15^##
低剂量组	30	85.35±8.15^**	56.92±4.28^**	11.34±1.22^**	57.74±4.48^**
高剂量组	60	66.64±8.32^**△△	47.30±5.67^**△△	14.07±1.82^**△△	48.91±4.25^**△△
注: 与正常组相比, ^##P < 0.01;与模型组相比, ^{* *}P < 0.01;与低剂量组相比, ^△△P < 0.01。

下载: 导出CSV

表 3 丹参酮ⅡA对ApoE^-/-小鼠血清中炎症因子含量的影响(x±s, pg · mL^-1, n=9)

Table 3. Effect of tanshinone ⅡA on the contents of serum inflammatory factors in ApoE^-/- mice (x±s, pg · mL^-1, n=9)

组别	剂量/(mg·kg^-1)	IL-1β	IL-6	TNF-α	IL-10
正常组	-	81.15±2.53	72.99±2.97	112.83±7.53	300.21±5.81
模型组	-	121.94±6.41^##	137.09±5.73^##	174.09±6.02^##	216.67±10.77^##
低剂量组	30	100.55±5.75^**	112.47±9.24^**	148.53±5.90^**	249.50±6.94^**
高剂量组	60	92.50±6.28^**△	93.21±4.18^**△△	130.50±7.40^**△△	270.76±8.88^**△△
注: 与正常组相比, ^##P < 0.01;与模型组相比, ^{* *}P < 0.01;与低剂量组相比，^△P < 0.05, ^△△P < 0.01。

下载: 导出CSV

参考文献(26)

[1]	CARNEY RM, FREEDLAND KE. Depression, mortality, and medical morbidity in patients with coronary heart disease[J]. Biol Psychiatry, 2003, 54(3): 241-247. doi: 10.1016/S0006-3223(03)00111-2
[2]	THOMBS BD, BASS EB, FORD DE, et al. Prevalence of depression in survivors of acute myocardial infarction[J]. J Gen Intern Med, 2006, 21(1): 30-38. doi: 10.1111/j.1525-1497.2005.00269.x
[3]	RUO B, RUMSFELD JS, PIPKIN S, et al. Relation between depressive symptoms and treadmill exercise capacity in the heart and soul study[J]. Am J Cardiol, 2004, 94(1): 96-99. doi: 10.1016/j.amjcard.2004.03.035
[4]	MALLIK S, KRUMHOLZ HM, LIN ZQ, et al. Patients with depressive symptoms have lower health status benefits after coronary artery bypass surgery[J]. Circulation, 2005, 111(3): 271-277. doi: 10.1161/01.CIR.0000152102.29293.D7
[5]	MOUSSAVI S, CHATTERJI S, VERDES E, et al. Depression, chronic diseases, and decrements in health: Results from the World Health Surveys[J]. Lancet, 2007, 370(9590): 851-858. doi: 10.1016/S0140-6736(07)61415-9
[6]	NAISMITH SL, GLOZIER N, BURKE D, et al. Early intervention for cognitive decline: Is there a role for multiple medical or behavioural interventions?[J]. Early Interv Psychiatry, 2009, 3(1): 19-27. doi: 10.1111/j.1751-7893.2008.00102.x
[7]	O'NEIL A, SANDERSON K, OLDENBURG B. Depression as a predictor of work resumption following myocardial infarction (MI): A review of recent research evidence[J]. Health Qual Life Outcomes, 2010, 8: 95. doi: 10.1186/1477-7525-8-95
[8]	ALEXANDER RW. Inflammation and coronary artery disease[J]. N Engl J Med, 1994, 331(7): 468-469. doi: 10.1056/NEJM199408183310709
[9]	TALEB S. Inflammation in atherosclerosis[J]. Arch Cardiovasc Dis, 2016, 109(12): 708-715. doi: 10.1016/j.acvd.2016.04.002
[10]	WIRTZ PH, VON KÄNEL R. Psychological stress, inflammation, and coronary heart disease[J]. Curr Cardiol Rep, 2017, 19(11): 111. doi: 10.1007/s11886-017-0919-x
[11]	VALKANOVA V, EBMEIER KP, ALLAN CL. CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies[J]. J Affect Disord, 2013, 150(3): 736-744. doi: 10.1016/j.jad.2013.06.004
[12]	KÖHLER CA, FREITAS TH, MAES M, et al. Peripheral cytokine and chemokine alterations in depression: A meta-analysis of 82 studies[J]. Acta Psychiatr Scand, 2017, 135(5): 373-387. doi: 10.1111/acps.12698
[13]	MARTIN M, REHANI K, JOPE RS, et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3[J]. Nat Immunol, 2005, 6(8): 777-784. doi: 10.1038/ni1221
[14]	WANG HZ, BROWN J, GU Z, et al. Convergence of the mammalian target of rapamycin complex 1-and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response[J]. J Immunol, 2011, 186(9): 5217-5226. doi: 10.4049/jimmunol.1002513
[15]	SUN DD, SHEN M, LI JY, et al. Cardioprotective effects of tanshinone ⅡA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy[J]. Cardiovasc Diabetol, 2011, 10: 4. doi: 10.1186/1475-2840-10-4
[16]	TANG FT, CAO Y, WANG TQ, et al. Tanshinone ⅡA attenuates atherosclerosis in ApoE^-/- mice through down-regulation of scavenger receptor expression[J]. Eur J Pharmacol, 2011, 650(1): 275-284. doi: 10.1016/j.ejphar.2010.07.038
[17]	WANG HQ, TONG Y, XIAO D, et al. Involvement of mTOR-related signaling in antidepressant effects of Sophoraflavanone G on chronically stressed mice[J]. Phytother Res, 2020, 34(9): 2246-2257. doi: 10.1002/ptr.6675
[18]	GAO J, YANG GQ, PI RB, et al. Tanshinone ⅡA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis[J]. Transl Res, 2008, 151(2): 79-87. doi: 10.1016/j.trsl.2007.11.005
[19]	SUN DD, WANG HC, WANG XB, et al. Tanshinone ⅡA: A new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels[J]. Eur J Pharmacol, 2008, 590(1/2/3): 317-321.
[20]	ZHANG Z, LAM TN, ZUO Z. Radix Puerariae: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use[J]. J Clin Pharmacol, 2013, 53(8): 787-811.
[21]	ZHANG Y, WEI L, SUN D, et al. Tanshinone ⅡA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats[J]. Diabetes Obes Metab, 2010, 12(4): 316-322. doi: 10.1111/j.1463-1326.2009.01166.x
[22]	XU M, CAO FL, ZHANG YF, et al. Tanshinone ⅡA therapeutically reduces LPS-induced acute lung injury by inhibiting inflammation and apoptosis in mice[J]. Acta Pharmacol Sin, 2015, 36(2): 179-187. doi: 10.1038/aps.2014.112
[23]	WEN JX, CHANG YM, HUO SS, et al. Tanshinone ⅡA attenuates atherosclerosis via inhibiting NLRP3 inflammasome activation[J]. Aging, 2020, 13(1): 910-932.
[24]	BEUREL E, TOUPS M, NEMEROFF CB. The bidirectional relationship of depression and inflammation: Double trouble[J]. Neuron, 2020, 107(2): 234-256. doi: 10.1016/j.neuron.2020.06.002
[25]	SU WJ, ZHANG Y, CHEN Y, et al. NLRP3 gene knockout blocks NF-κB and MAPK signaling pathway in CUMS-induced depression mouse model[J]. Behav Brain Res, 2017, 322(Pt A): 1-8.
[26]	WU ZT, WANG GH, WEI YY, et al. PI3K/AKT/GSK3β/CRMP-2-mediated neuroplasticity in depression induced by stress[J]. Neuroreport, 2018, 29(15): 1256-1263. doi: 10.1097/WNR.0000000000001096